Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma.

María-Victoria Mateos,Ajai Chari,Saad Z Usmani,Hartmut Goldschmidt,Katja Weisel,Keqin Qi,Anil Londhe,Sandhya Nair,Xiwu Lin,Lixia Pei,Eric Ammann,Rachel Kobos,Jennifer Smit,Trilok Parekh,Alexander Marshall,Mary Slavcev,Philippe Moreau

Clinical lymphoma, myeloma & leukemia（2023）

引用 1|浏览6

暂无评分

摘要

Teclistamab showed significantly improved effectiveness versus PC on all outcomes, highlighting its clinical benefit in patients with TCE RRMM and limited treatment options.

查看译文

关键词

B-cell maturation antigen,Bispecific antibody,Comparative effectiveness,Indirect treatment comparison,MajesTEC-1

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要